Literature DB >> 20185297

Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer.

Eva Karamitopoulou1, Pierlorenzo Pallante, Inti Zlobec, Luigi Tornillo, Vincenza Carafa, Thomas Schaffner, Markus Borner, Ioannis Diamantis, Francesco Esposito, Thomas Brunner, Arthur Zimmermann, Antonella Federico, Luigi Terracciano, Alfredo Fusco.   

Abstract

Polycomb group (PcG) proteins function as multiprotein complexes and are part of a gene regulatory mechanism that determines cell fate during normal and pathogenic development. Several studies have implicated the deregulation of different PcG proteins in neoplastic progression. Pancreatic ductal adenocarcinoma is an aggressive neoplasm that follows a multistep model of progression through precursor lesions called pancreatic intraepithelial neoplasia (PanIN). Aim of this study was to investigate the role of PcG protein CBX7 in pancreatic carcinogenesis and to evaluate its possible diagnostic and prognostic significance. We analysed by immunohistochemistry the expression of CBX7 in 210 ductal pancreatic adenocarcinomas from resection specimens, combined on a tissue microarray (TMA) including additional 40 PanIN cases and 40 normal controls. The results were evaluated by using receiver operating characteristic (ROC) curve analysis for the selection of cut-off scores and correlated to the clinicopathological parameters of the tumours and the outcome of the patients. Expression of E-cadherin, a protein positively regulated by CBX7, was also assessed. A significantly differential, and progressively decreasing CBX7 protein expression was found between normal pancreatic tissue, PanINs and invasive ductal adenocarcinoma. Loss of CBX7 expression was associated with increasing malignancy grade in pancreatic adenocarcinoma, whereas the maintenance of CBX7 expression showed a trend toward a longer survival. Moreover, loss of E-cadherin expression was associated with loss of CBX7 and with a trend towards worse patient survival. These results suggest that CBX7 plays a role in pancreatic carcinogenesis and that its loss of expression correlates to a more aggressive phenotype. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20185297     DOI: 10.1016/j.ejca.2010.01.033

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  49 in total

Review 1.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

Review 2.  Inherited genetic susceptibility to multiple myeloma.

Authors:  G J Morgan; D C Johnson; N Weinhold; H Goldschmidt; O Landgren; H T Lynch; K Hemminki; R S Houlston
Journal:  Leukemia       Date:  2013-11-19       Impact factor: 11.528

Review 3.  Polycomb protein family member CBX7 plays a critical role in cancer progression.

Authors:  Pierlorenzo Pallante; Floriana Forzati; Antonella Federico; Claudio Arra; Alfredo Fusco
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

Review 4.  Polycomb and the emerging epigenetics of pancreatic cancer.

Authors:  Adrienne Grzenda; Tamas Ordog; Raul Urrutia
Journal:  J Gastrointest Cancer       Date:  2011-06

Review 5.  Epigenetic regulation by polycomb group complexes: focus on roles of CBX proteins.

Authors:  Rong-gang Ma; Yang Zhang; Ting-ting Sun; Bo Cheng
Journal:  J Zhejiang Univ Sci B       Date:  2014-05       Impact factor: 3.066

6.  CBX7 is a tumor suppressor in mice and humans.

Authors:  Floriana Forzati; Antonella Federico; Pierlorenzo Pallante; Adele Abbate; Francesco Esposito; Umberto Malapelle; Romina Sepe; Giuseppe Palma; Giancarlo Troncone; Marzia Scarfò; Claudio Arra; Monica Fedele; Alfredo Fusco
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

7.  CBX7 Expression in Oncocytic Thyroid Neoplastic Lesions (Hürthle Cell Adenomas and Carcinomas).

Authors:  Mario Monaco; Gennaro Chiappetta; Concetta Aiello; Antonella Federico; Romina Sepe; Daniela Russo; Alfredo Fusco; Pierlorenzo Pallante
Journal:  Eur Thyroid J       Date:  2014-10-15

8.  Oncogenic role of the chromobox protein CBX7 in gastric cancer.

Authors:  Xiao-Wei Zhang; Li Zhang; Wei Qin; Xiao-Hong Yao; Lei-Zhen Zheng; Xin Liu; Jin Li; Wei-Jian Guo
Journal:  J Exp Clin Cancer Res       Date:  2010-08-19

Review 9.  H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.

Authors:  J N Nichol; D Dupéré-Richer; T Ezponda; J D Licht; W H Miller
Journal:  Adv Cancer Res       Date:  2016-06-17       Impact factor: 6.242

10.  Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment.

Authors:  Nunzio Antonio Cacciola; Romina Sepe; Floriana Forzati; Antonella Federico; Simona Pellecchia; Umberto Malapelle; Alfonso De Stefano; Danilo Rocco; Alfredo Fusco; Pierlorenzo Pallante
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-07-28       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.